N6-methyladenosine (m6A)
(Synonyms: N6-甲基腺苷; 6-Methyladenosine; N-Methyladenosine) 目录号 : GC14698
An adenosine analog
Cas No.:1867-73-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
N6-methyladenosine (m6A or N6m), an adenosine agonist, of an ED50 value of 17.250 µM [1], is a regulator of adenylate cyclase [2]. As a modification in the messenger RNA (mRNA), it is the most prevalent internal (non-cap) modification of mRNA in all higher eukaryotes. It is involved in the regulation of mRNA stability [3].
Adenylate cyclase catalyzes the formation of cyclic adenosine 3’,5’-monophosphate (cAMP) from ATP [4]. In Calu-6 cells, cAMP increased the stability of human rennin mRNA [5].
Concentration-dependently, N6m prevented the accumulation of hemoglobin and inhibited the initiation of commitment to terminal maturation. Treatment with N6m made cell growth slower, but it did not substantially inhibit DNA synthesis and markedly decrease viability and clonogenic potential of MEL cells. In MEL cells, treatment with N6m resulted in a decrease in the accumulation of βmajor globin mRNA in cytoplasm and affected the structural integrity of this mRNA. The inhibition of commitment induced by N6m was potentiated by adenine, l-homocysteine and/or l-methionine. Adenine, l-homocysteine and l-methionine are involved in the active methylation cycle [6].
In mammals, RNA m6A modification preferentially occurs within the consensus sequence RRACH (R = G or A; H = A, C or U) in 3’ UTRs and gene coding regions. That means m6A plays fundamental roles in the control of RNA processing and translational [7].
References:
[1]. Ribeiro JA and Sebastio AM. On the type of receptor involved in the inhibitory action of adenosine at the neuromuscular junction. Br J Pharmacol, 1985, 84(4):911-8.
[2]. Londos C, Wolff J and Cooper DMF. Adenosine as a regulator of adenylate cyclase[M]//Purinergic receptors. Springer Netherlands, 1981:287-323.
[3]. Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature, 2014, 505(7481): 117-120.
[4]. Salomon Y, Londos C and Rodbell M. A highly sensitive adenylate cyclase assay. Analytical biochemistry, 1974, 58(2): 541-548.
[5]. Sinn P L and Sigmund CD. Human renin mRNA stability is increased in response to cAMP in Calu-6 cells. Hypertension, 1999, 33(3): 900-905.
[6]. Vizirianakis IS, Wong W and Tsiftsoglou AS. Analysis of the inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation by N 6-methyladenosine. Biochemical pharmacology, 1992, 44(5): 927-936.
[7]. Zhao X, Yang Y, Sun BF, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell research, 2014, 24(12): 1403-1419.
| Cas No. | 1867-73-8 | SDF | |
| 别名 | N6-甲基腺苷; 6-Methyladenosine; N-Methyladenosine | ||
| 化学名 | (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(methylamino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol | ||
| Canonical SMILES | CNC1=C(N=CN2[C@@]3([H])[C@@](O)([H])[C@@](O)([H])[C@@](O3)([H])CO)C2=NC=N1 | ||
| 分子式 | C11H15N5O4 | 分子量 | 281.27 |
| 溶解度 | ≥ 12.2mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5553 mL | 17.7765 mL | 35.553 mL |
| 5 mM | 0.7111 mL | 3.5553 mL | 7.1106 mL |
| 10 mM | 0.3555 mL | 1.7777 mL | 3.5553 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。